SCHEMBL12633875

SCHEMBL12633875

CC1(C)Cc2sccc2CN1C(=O)c1cc2ncc(Cl)cn2n1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 13/20 0.48
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
KDM4E B2RXH2 2/20 0.37
LMNA P02545 1/20 0.37
TDP1 Q9NUW8 2/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
ESR2 Q92731 2/20 0.35
POLB P06746 1/20 0.35
NR4A1 P22736 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TSHR P16473 1/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8222026 0.89 GRM5 (0.47) GRM5ALDH1A1HPGDKDM4ELMNA
SCHEMBL8224326 0.88 GRM5 (0.61) GRM5ALDH1A1HPGDKDM4ETDP1
SCHEMBL1010760 0.86 GRM5 (0.45) GRM5ALDH1A1HPGDKDM4ELMNA
SCHEMBL13719951 0.84 GRM5 (0.33) GRM5ALDH1A1KDM4EMAPTRAB9A
SCHEMBL1010151 0.80 GRM5 (0.44) GRM5ALDH1A1HPGDKDM4ELMNA
SCHEMBL1868849 0.79 GRM5 (0.67) GRM5ALDH1A1TDP1GAAMAPT
SCHEMBL1870033 0.78 GRM5 (0.48) GRM5ALDH1A1HPGDKDM4ELMNA
SCHEMBL1869308 0.78 GRM5 (0.56) GRM5ALDH1A1HPGDKDM4ELMNA
SCHEMBL13719512 0.76 GRM5 (0.41) GRM5ALDH1A1TDP1GAAMAPT
SCHEMBL1010188 0.73 POLB (0.53) GRM5ALDH1A1HPGDKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947689-B2 Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators MERZ PHARMA GMBH & CO. KGAA (DE) 2011-05-24 US disclosed
US-7947689-B2 Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators MERZ PHARMA GMBH & CO. KGAA (DE) 2011-05-24 US disclosed
EP-2054421-B1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO KGAA (DE) 2010-11-17 EP disclosed
US-20080039476-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine MERZ PHARMA GMBH & CO. KGAA (DE) 2008-02-14 US disclosed
US-20080039476-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine MERZ PHARMA GMBH & CO. KGAA (DE) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039476-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine GRM5, GRM3, GRM1 GRM5 1/4885ALDH1A1 4053/4885HPGD 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.